

Julio Benitez

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/11052335/julio-benitez-publications-by-year.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

47
papers

1,965
citations

27
h-index

44
g-index

47
ext. papers

2,108
ext. citations

4.6
avg, IF

4.09
L-index

#	Paper	IF	Citations
47	ABCB1 polymorphisms are associated with cyclosporine-induced nephrotoxicity and gingival hyperplasia in renal transplant recipients. <i>European Journal of Clinical Pharmacology</i> , 2013 , 69, 385-93	2.8	30
46	CYP2C8*3 polymorphism and donor age are associated with allograft dysfunction in kidney transplant recipients treated with calcineurin inhibitors. <i>Journal of Clinical Pharmacology</i> , 2013 , 53, 427-34	2.9	17
45	Comparative cytochrome p450 in vitro inhibition by atypical antipsychotic drugs. <i>ISRN Pharmacology</i> , 2013 , 2013, 792456		9
44	Haplotypes in the 5' untranslated region of the CYP1A2 gene are inversely associated with lung cancer risk but do not correlate with caffeine metabolism. <i>Environmental and Molecular Mutagenesis</i> , 2013 , 54, 124-32	3.2	8
43	Impact of genetic polymorphisms on tacrolimus pharmacokinetics and the clinical outcome of renal transplantation. <i>Transplant International</i> , 2012 , 25, 471-80	3	61
42	GST polymorphisms interact with dietary factors to modulate lung cancer risk: study in a high-incidence area. <i>Nutrition and Cancer</i> , 2010 , 62, 750-8	2.8	16
41	Pharmacogenetic testing and therapeutic drug monitoring are complementary tools for optimal individualization of drug therapy. <i>European Journal of Clinical Pharmacology</i> , 2010 , 66, 755-74	2.8	48
40	CYP1A1 gene polymorphisms increase lung cancer risk in a high-incidence region of Spain: a case control study. <i>BMC Cancer</i> , 2010 , 10, 463	4.8	19
39	Effect of neurotransmitters on NADPH-cytochrome P450 reductase in vitro activity. <i>Drug Metabolism Letters</i> , 2007 , 1, 172-5	2.1	2
38	Adenosine triphosphate-binding cassette B1 (ABCB1) (multidrug resistance 1) G2677T/A gene polymorphism is associated with high risk of lung cancer. <i>Cancer</i> , 2006 , 107, 2850-7	6.4	50
37	The effect of CYP2J2, CYP3A4, CYP3A5 and the MDR1 polymorphisms and gender on the urinary excretion of the metabolites of the H ₁ -receptor antihistamine ebastine: a pilot study. <i>British Journal of Clinical Pharmacology</i> , 2006 , 62, 177-86	3.8	20
36	Differences in CYP3A5*3 genotype distribution and combinations with other polymorphisms between Spaniards and Other Caucasian populations. <i>Therapeutic Drug Monitoring</i> , 2005 , 27, 819-21	3.2	39
35	Evaluation of a drug-drug interaction alert structure through the retrospective analysis of statins-macrolides co-prescriptions. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2005 , 96, 289-94	3.1	5
34	Using a computerized drug prescription screening system to trace drug interactions in an outpatient setting. <i>Annals of Pharmacotherapy</i> , 2004 , 38, 1301-6	2.9	8
33	Early detection of drug interactions utilizing a computerized drug prescription handling system-focus on cerivastatin-gemfibrozil. <i>European Journal of Clinical Pharmacology</i> , 2004 , 59, 917-21	2.8	2
32	Potential role of cerebral cytochrome P450 in clinical pharmacokinetics: modulation by endogenous compounds. <i>Clinical Pharmacokinetics</i> , 2004 , 43, 693-706	6.2	45
31	Applicability of an assay for routine monitoring of highly variable concentrations of olanzapine based on HPLC with mass spectrometric detection. <i>Clinical Chemistry</i> , 2003 , 49, 2088-91	5.5	14

30	Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine. <i>Journal of Clinical Psychopharmacology</i> , 2003 , 23, 119-27	1.7	120
29	N-acetyltransferase 2 single-nucleotide polymorphisms and risk of gastric carcinoma. <i>European Journal of Clinical Pharmacology</i> , 2002 , 58, 115-8	2.8	17
28	Functionally active duplications of the CYP2D6 gene are more prevalent among larynx and lung cancer patients. <i>Oncology</i> , 2001 , 61, 59-63	3.6	35
27	Clinically significant pharmacokinetic interactions between dietary caffeine and medications. <i>Clinical Pharmacokinetics</i> , 2000 , 39, 127-53	6.2	207
26	Use of the mesoridazine/thioridazine ratio as a marker for CYP2D6 enzyme activity. <i>Therapeutic Drug Monitoring</i> , 2000 , 22, 397-401	3.2	34
25	Evaluation of caffeine as an in vivo probe for CYP1A2 using measurements in plasma, saliva, and urine. <i>Therapeutic Drug Monitoring</i> , 2000 , 22, 409-17	3.2	108
24	Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists. <i>Clinical Pharmacology and Therapeutics</i> , 1999 , 65, 369-76	6.1	92
23	Pharmacokinetic interaction of fluvoxamine and thioridazine in schizophrenic patients. <i>Journal of Clinical Psychopharmacology</i> , 1999 , 19, 494-9	1.7	49
22	Influence of genetic admixture on polymorphisms of drug-metabolizing enzymes: analyses of mutations on NAT2 and C gamma P2E1 genes in a mixed Hispanic population. <i>Clinical Pharmacology and Therapeutics</i> , 1998 , 63, 623-8	6.1	27
21	Effects of caffeine withdrawal from the diet on the metabolism of clozapine in schizophrenic patients. <i>Journal of Clinical Psychopharmacology</i> , 1998 , 18, 311-6	1.7	62
20	Analysis of midazolam and metabolites in plasma by high-performance liquid chromatography: probe of CYP3A. <i>Therapeutic Drug Monitoring</i> , 1998 , 20, 319-24	3.2	58
19	CYP2D6, NAT2 and CYP2E1 genetic polymorphisms in nonagenarians. <i>Age and Ageing</i> , 1997 , 26, 147-51	3	39
18	Molecular heterogeneity at the CYP2D gene locus in Nicaraguans: impact of gene-flow from Europe. <i>Pharmacogenetics and Genomics</i> , 1997 , 7, 337-40		20
17	Changes induced by ovariectomy on the acute effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in a model of rat poor metabolizer of debrisoquine. <i>Parkinsonism and Related Disorders</i> , 1996 , 2, 7-12	3.6	
16	Increased risk for hepatocellular carcinoma in NAT2-slow acetylators and CYP2D6-rapid metabolizers. <i>Pharmacogenetics and Genomics</i> , 1996 , 6, 501-12		54
15	CYP1A2 activity, gender and smoking, as variables influencing the toxicity of caffeine. <i>British Journal of Clinical Pharmacology</i> , 1996 , 41, 605-8	3.8	74
14	Debrisoquine oxidation polymorphism in patients with chronic inflammatory bowel disease. <i>Annals of Medicine</i> , 1995 , 27, 555-8	1.5	2
13	Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population. <i>Clinical Pharmacology and Therapeutics</i> , 1995 , 57, 265-9	6.1	154

12	Association between the oxidative polymorphism and early onset of Parkinson's disease. <i>Clinical Pharmacology and Therapeutics</i> , 1995 , 57, 291-8	6.1	59
11	Debrisoquin oxidation genotype and susceptibility to lung cancer. <i>Clinical Pharmacology and Therapeutics</i> , 1994 , 55, 10-4	6.1	45
10	Caffeine metabolism in a healthy Spanish population: N-acetylator phenotype and oxidation pathways. <i>Clinical Pharmacology and Therapeutics</i> , 1994 , 55, 293-304	6.1	62
9	Genetic basis for differences in debrisoquin polymorphism between a Spanish and other white populations. <i>Clinical Pharmacology and Therapeutics</i> , 1994 , 55, 412-7	6.1	43
8	Molecular analysis of the arylamine N-acetyltransferase polymorphism in a Spanish population. <i>Clinical Pharmacology and Therapeutics</i> , 1994 , 56, 202-9	6.1	28
7	Debrisoquine polymorphism: mechanism for very rapid oxidative phenotype. <i>Lancet, The</i> , 1993 , 341, 689	4.0	
6	Acute effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in a model of rat designated a poor metabolizer of debrisoquine. <i>Journal of Neurochemistry</i> , 1991 , 57, 81-7	6	38
5	Polymorphic oxidation of debrisoquine in lung cancer patients. <i>European Journal of Cancer & Clinical Oncology</i> , 1991 , 27, 158-61		17
4	Polymorphic oxidation of debrisoquine in women with breast cancer. <i>Oncology</i> , 1991 , 48, 107-10	3.6	21
3	Polymorphic oxidation of debrisoquine in bladder cancer. <i>Annals of Medicine</i> , 1990 , 22, 157-60	1.5	13
2	Assessment of the debrisoquin and dextromethorphan phenotyping tests by gaussian mixture distributions analysis. <i>Clinical Pharmacology and Therapeutics</i> , 1989 , 45, 328-33	6.1	43
1	Debrisoquin oxidation polymorphism in a Spanish population. <i>Clinical Pharmacology and Therapeutics</i> , 1988 , 44, 74-7	6.1	51